A Multiple-Dose Study in Participants With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics,and Pharmacodynamics of LY3502970
Latest Information Update: 05 Nov 2022
At a glance
- Drugs Orforglipron (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Sep 2022 Results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 26 Jul 2021 Status changed from active, no longer recruiting to completed.
- 06 Jul 2021 Status changed from recruiting to active, no longer recruiting.